Two-Year Outcomes Of Combined Deep Sclerectomy And Phacoemulsification Verses Istent Implantation And Phacoemulsification In Open Angle Glaucoma.
Published 2025 - 43rd Congress of the ESCRS
Reference: PP24.11 | Type: Free paper | DOI: 10.82333/1wnf-ez68
Authors: Kelly Ann Hutchinson* 1 , Mary Holdsworth 2 , Davin Johnson 1
1Queen's University,Kingston,Canada, 2University of Calgary,Calgary,Canada
Purpose
Compared the outcomes of combined iStent and phacoemulsification surgery to combined deep sclerectomy and phacoemulsification in management of cataract and open angle glaucoma.
Setting
King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia.
Methods
A retrospective comparison was performed on eyes that underwent combined phacoemulsification and deep sclerectomy (DS Group) surgery or combined phacoemulsification and iStent inject W (iStent group) from 2017 to 2022. The primary outcome measures were changes in intraocular pressure (IOP), medication burden, complication rate, and the need for further intervention or glaucoma surgery, and success rates.
Results
One hundred and one eyes were included in the current study. At 2 years postoperatively, the mean IOP was 14.9±4.46 mmHg for the DS group and 15.2±3.5 mmHg for the iStent group. By 2 years postoperatively the mean reduction in the medication burden was similar between groups (1.3±1.7 medications). The rate of complications and the need for further intervention was higher in the DS group compared to the iStent group.
Conclusions
Phacoemulsification combined with either deep sclerectomy or iStent injection is effective and safe for treating patients with cataracts and open angle glaucoma. However, ancillary procedures may be required in patients who undergo combined surgery with deep sclerectomy.